A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs AZD 5423 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Apr 2012 Actual end date December 2011 added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Actual patient no 96 added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.